Liver-stage malaria parasites vulnerable to diverse chemical scaffolds

Human malaria infection begins with a one-time asymptomatic liver stage followed by a cyclic symptomatic blood stage. All high-throughput malaria drug discovery efforts have focused on the cyclic blood stage, which has limited potential for the prophylaxis, transmission blocking, and eradication efforts that will be needed in the future. To address these unmet needs, a high-throughput phenotypic liver-stage Plasmodium parasite screen was developed to systematically identify molecules with liver-stage efficacy. The screen recapitulates liver-stage infection by isolating luciferase-expressing Plasmodium berghei parasites directly from the salivary glands of infected mosquitoes, adding them to confluent human liver cells in 384-well plates, and measuring luciferase activity after a suitable incubation period. Screening 5,375 known bioactive compounds identified 37 liver-stage malaria inhibitors with diverse modes of action, as shown by inhibition time course experiments. Further analysis of the hits in the Food and Drug Administration-approved drug subset revealed compounds that seem to act specifically on the liver stage of infection, suggesting that this phase of the parasite’s life cycle presents a promising area for new drug discovery. Notably, many active compounds in this screen have molecular structures and putative targets distinctly different from those of known antimalarial agents.

[1]  J. Clardy,et al.  Characterization of Plasmodium Liver Stage Inhibition by Halofuginone , 2012, ChemMedChem.

[2]  M. Mota,et al.  A toolbox to study liver stage malaria. , 2011, Trends in parasitology.

[3]  M. Aepfelbacher,et al.  Organelle segregation into Plasmodium liver stage merozoites , 2011, Cellular microbiology.

[4]  M. Mota,et al.  The Next Opportunity in Anti-Malaria Drug Discovery: The Liver Stage , 2011, PLoS pathogens.

[5]  X. Su,et al.  Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets , 2011, Science.

[6]  François Nosten,et al.  The reality of using primaquine , 2010, Malaria Journal.

[7]  Bruce Russell,et al.  Spiroindolones, a Potent Compound Class for the Treatment of Malaria , 2010, Science.

[8]  A. Hasnat,et al.  Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study. , 2010, Clinical therapeutics.

[9]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[10]  Anang A. Shelat,et al.  Chemical genetics of Plasmodium falciparum , 2010, Nature.

[11]  A. Azad,et al.  Transcriptional Analysis of the Pre-Erythrocytic Stages of the Rodent Malaria Parasite, Plasmodium yoelii , 2010, PloS one.

[12]  Yingyao Zhou,et al.  A Systems-Based Analysis of Plasmodium vivax Lifecycle Transcription from Human to Mosquito , 2010, PLoS neglected tropical diseases.

[13]  Robert W. Sauerwein,et al.  Visualisation and Quantitative Analysis of the Rodent Malaria Liver Stage by Real Time Imaging , 2009, PloS one.

[14]  L. Rénia,et al.  A pre-emptive strike against malaria's stealthy hepatic forms , 2009, Nature Reviews Drug Discovery.

[15]  P. Koehler,et al.  History of Methysergide in Migraine , 2008, Cephalalgia : an international journal of headache.

[16]  Peter G. Schultz,et al.  In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen , 2008, Proceedings of the National Academy of Sciences.

[17]  Nicholas J White,et al.  Vivax malaria: neglected and not benign. , 2007, The American journal of tropical medicine and hygiene.

[18]  R. Sauerwein,et al.  A Plant-Derived Morphinan as a Novel Lead Compound Active against Malaria Liver Stages , 2006, PLoS medicine.

[19]  D. Wirth,et al.  High-Throughput Plasmodium falciparum Growth Assay for Malaria Drug Discovery , 2006, Antimicrobial Agents and Chemotherapy.

[20]  Ana Rodriguez,et al.  The silent path to thousands of merozoites: the Plasmodium liver stage , 2006, Nature Reviews Microbiology.

[21]  V. Roche The chemically elegant proton pump inhibitors. , 2006, American journal of pharmaceutical education.

[22]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[23]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[24]  S. Kappe,et al.  Malaria liver stage culture: in vitro veritas? , 2006, The American journal of tropical medicine and hygiene.

[25]  Elisabetta Pizzi,et al.  Genome-wide identification of genes upregulated at the onset of gametocytogenesis in Plasmodium falciparum. , 2005, Molecular and biochemical parasitology.

[26]  J. Baird,et al.  Effectiveness of antimalarial drugs. , 2005, The New England journal of medicine.

[27]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[28]  S. Hoffman,et al.  Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Patricia De la Vega,et al.  Discovery of Gene Function by Expression Profiling of the Malaria Parasite Life Cycle , 2003, Science.

[30]  F. Cohen,et al.  Expression profiling of the schizont and trophozoite stages of Plasmodium falciparum with a long-oligonucleotide microarray , 2003, Genome Biology.

[31]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[32]  D. Kyle,et al.  Efficacy of Proton Pump Inhibitor Drugs against Plasmodium falciparum In Vitro and Their Probable Pharmacophores , 2002, Antimicrobial Agents and Chemotherapy.

[33]  J. Sachs,et al.  The economic and social burden of malaria , 2002, Nature.

[34]  Ogobara K. Doumbo,et al.  The pathogenic basis of malaria , 2002, Nature.

[35]  R. Rosenberg,et al.  Continuous in vitro propagation of the malaria parasite Plasmodium vivax. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[37]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[38]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[39]  L. Scott,et al.  Telmisartan , 2012, Drugs.

[40]  Q. Bassat,et al.  Defying malaria: Fathoming severe Plasmodium vivax disease , 2011, Nature Medicine.

[41]  T. Andersson,et al.  Stereoselective Disposition of Proton Pump Inhibitors , 2008, Clinical drug investigation.

[42]  T. Andersson,et al.  Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole , 2001, Clinical pharmacokinetics.